Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATHX NASDAQ:CALA NASDAQ:DVAX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATHXAthersys$0.00$0.01▼$1.99$833K-0.91.77 million shs4 shsCALACalithera Biosciences$0.00$0.00$0.00▼$0.00N/A-1.05757 shs190 shsDVAXDynavax Technologies$15.50$15.51$9.20▼$15.73$1.82B0.972.20 million shsN/AA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATHXAthersys0.00%0.00%0.00%0.00%0.00%CALACalithera Biosciences0.00%-66.67%-66.67%-50.00%0.00%DVAXDynavax Technologies0.00%0.00%0.00%0.00%+59.47%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATHXAthersys$0.00$0.01▼$1.99$833K-0.91.77 million shs4 shsCALACalithera Biosciences$0.00$0.00$0.00▼$0.00N/A-1.05757 shs190 shsDVAXDynavax Technologies$15.50$15.51$9.20▼$15.73$1.82B0.972.20 million shsN/AA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATHXAthersys0.00%0.00%0.00%0.00%0.00%CALACalithera Biosciences0.00%-66.67%-66.67%-50.00%0.00%DVAXDynavax Technologies0.00%0.00%0.00%0.00%+59.47%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATHXAthersys 0.00N/AN/AN/ACALACalithera Biosciences 0.00N/AN/AN/ADVAXDynavax Technologies 2.00Hold$32.00106.45% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATHXAthersys$146K0.00N/AN/A($1.33) per share0.00CALACalithera BiosciencesN/AN/AN/AN/AN/AN/ADVAXDynavax Technologies$330.51M5.51$0.16 per share97.88$4.54 per share3.41Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATHXAthersys-$72.53M-$2.03N/AN/AN/AN/AN/A-223.03%N/ACALACalithera Biosciences-$39.65MN/AN/AN/AN/AN/AN/AN/A5/13/2026 (Estimated)DVAXDynavax Technologies$27.31M-$0.37N/A31.63N/A-13.13%7.18%4.08%N/ALatest CALA, DVAX, and ATHX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026N/ACALACalithera Biosciences-$4.8020N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthATHXAthersysN/AN/AN/AN/AN/ACALACalithera BiosciencesN/AN/AN/AN/AN/ADVAXDynavax TechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATHXAthersysN/A0.060.06CALACalithera BiosciencesN/AN/AN/ADVAXDynavax Technologies0.417.626.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATHXAthersys19.35%CALACalithera BiosciencesN/ADVAXDynavax Technologies96.96%Insider OwnershipCompanyInsider OwnershipATHXAthersys0.03%CALACalithera Biosciences6.60%DVAXDynavax Technologies2.98%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATHXAthersys2461.72 million61.70 millionNo DataCALACalithera Biosciences603.86 million4.55 millionNot OptionableDVAXDynavax Technologies350117.43 million113.93 millionOptionableCALA, DVAX, and ATHX HeadlinesRecent News About These CompaniesA Look At Dynavax Technologies (DVAX) Valuation As Pipeline Prospects Meet Conflicting Fair Value EstimatesFebruary 10, 2026 | finance.yahoo.comIs It Time To Reassess Dynavax (DVAX) After The Agreed Sanofi Cash Acquisition DealFebruary 10, 2026 | finance.yahoo.comDynavax Technologies (DVAX) price target decreased by 14.58% to 20.91February 4, 2026 | msn.comDynavax Technologies (DVAX) price target increased by 15.66% to 24.48January 15, 2026 | msn.comDynavax gains on disclosure another bidder interested after deal announcedJanuary 12, 2026 | msn.comIs It Time To Reassess Dynavax Technologies (DVAX) After Its Recent Share Price SurgeJanuary 10, 2026 | finance.yahoo.com$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Dynavax Technologies Corporation (NASDAQ: DVAX)January 5, 2026 | prnewswire.comDynavax Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dynavax Technologies Corporation - DVAXDecember 30, 2025 | prnewswire.comCORRECTING and REPLACING Dynavax Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dynavax Technologies Corporation - DVAXDecember 30, 2025 | businesswire.comDynavax Technologies (NASDAQ:DVAX) COO Sells $464,700.00 in StockDecember 30, 2025 | insidertrades.comDynavax Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dynavax Technologies Corporation - DVAXDecember 29, 2025 | businesswire.comSanofi (SNY) to Acquire Dynavax Technologies Corporation (DVAX)December 28, 2025 | msn.comDynavax Technologies (DVAX) Shares Are Trending Overnight — Here's WhyDecember 25, 2025 | benzinga.comWhy Dynavax Stock Soared TodayDecember 24, 2025 | fool.comDynavax (DVAX) Stock Surges in Premarket on $2.2B Sanofi BuyoutDecember 24, 2025 | tokenist.comTDynavax Technologies Stock Soars on Buyout BuzzDecember 24, 2025 | schaeffersresearch.comDynavax Technologies, Omeros, Agios Pharmaceuticals, Nike And Other Big Stocks Moving Higher On WednesdayDecember 24, 2025 | benzinga.comShareholder Alert: The Ademi Firm investigates whether Dynavax Technologies Corporation is obtaining a Fair Price for its Public ShareholdersDecember 24, 2025 | prnewswire.comShares of Dynamax Are Up Nearly 40% Today. Here's Why The Stock Is FlyingDecember 24, 2025 | investopedia.comSanofi to acquire Dynavax in $2.2B Deal to boost adult vaccinesDecember 24, 2025 | proactiveinvestors.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCALA, DVAX, and ATHX Company DescriptionsAthersys NASDAQ:ATHXAthersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. The company was founded in 1995 and is headquartered in Cleveland, Ohio.Calithera Biosciences NASDAQ:CALA$0.0001 0.00 (0.00%) As of 05/6/2026 11:00 AM EasternCalithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.Dynavax Technologies NASDAQ:DVAXDynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
